NCT03004534 - A Study to Evaluate Changes in Human Breast Cancer Tissue Following Short-Term Use of Darolutamide | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 5, 2017

Primary Completion Date

February 14, 2019

Study Completion Date

March 13, 2019

Conditions

Breast Cancer Female

Interventions

DRUG

darolutamide

Oral 300 mg tablets; 600 mg (2 x 300 mg tablets) taken twice per day, to a daily dose of 1200 mg.

Trial Locations (14)

UF Health Cancer Center - Orlando Health, Orlando

Department of Women's Health, Tübingen

Interdisziplinares Onkologisches Zentrum, München

Torrance Memorial Physician Network, Cancer Care Associates, Redondo Beach

Universitatsklinikum Erlangen, Erlangen

Valley Breast Care and Women's Health Center, Los Angeles

Central Coast Medical Oncology, Santa Maria

UCLA, Los Angeles

Cross Cancer Institute, Edmonton

(CIUSSS) de l'Est-de-l'Île-de-Montréal - l'Hôpital Maisonneuve-Rosemont, Montreal

Centre Hospitalier de l'Université de Montréal (CHUM), Montreal

Jewish General Hospital, Montreal

McGill University Hospital, Montreal

Centre Hospitalier Affilie Universitaire De Quebec - Hospital Du Saint-Sacrement, Québec